An ongoing phase 2, multi-centre, open-label, study of WTX101 in Wilson disease patients – Early observations
Objective: The aim of this ongoing study is to evaluate the efficacy and safety of WTX101 in newly diagnosed Wilson Disease patients. Background: WTX101 (bis-choline…Supplement use in PD is associated with delayed initiation of dopaminergic therapy
Objective: To describe supplement use among early PD patients, and to determine its association with time to initiation of dopamine replacement therapy (DRT). Background: Earlier…PD COMM Pilot: A pilot randomised controlled trial of Lee Silverman voice treatment (LSVT) versus NHS speech and language therapy versus no intervention in Parkinson’s
Objective: To evaluate the feasibility of a full scale trial on the effectiveness and cost-effectiveness of two types of speech and language therapy (SLT) for…Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity
Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…The CNS moving voice program: Implementation of a dual voice and physical exercise program for Parkinson’s disease: An applicability study
Objective: To test the applicability of a rehabilitation program for people with Parkinson´s disease that combines speech and motor exercises (The CNS Moving Voice Program).…Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: The objective was to determine whether Nilotinib crosses the blood brain barrier (BBB). Background: Parkinson's disease (PD) involves death of dopamine producing neurons in…Patient case reports supporting a long-term effect of sub-anesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias
Objective: To evaluate possible long-term anti-dyskinetic activity of low-dose sub-anesthetic ketamine infusion from a retrospective chart review. Background: Repurposing drugs that have already been proven…Best supportive care or palliative care for late stage Parkinsonian syndromes?
Objective: To ask whether best supportive care might be more suitable for patients with Parkinson's disease (PD) and Parkinsonian syndromes and their family than palliative…Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study
Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study
Objective: To examine whether the response to an inhaled levodopa formulation (CVT-301; at 35 and 50 mg per dose) is dependent on baseline patient characteristics.…
- « Previous Page
- 1
- …
- 128
- 129
- 130
- 131
- 132
- …
- 207
- Next Page »